{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:01:31Z","timestamp":1768543291785,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ijantimicag.2011.02.007","type":"journal-article","created":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T11:17:42Z","timestamp":1303298262000},"page":"558-561","source":"Crossref","is-referenced-by-count":24,"title":["Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA)"],"prefix":"10.1016","volume":"37","author":[{"given":"Steven N.","family":"Leonard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong G.","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Zolotarev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona V.","family":"Grigoryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0005","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.00582-08","article-title":"Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)","volume":"46","author":"Rybak","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0010","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1086\/596629","article-title":"Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia","volume":"199","author":"Maor","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0015","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1592\/phco.28.4.458","article-title":"Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious Gram-positive infections","volume":"28","author":"Leonard","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0020","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/AAC.01544-08","article-title":"Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"53","author":"Leonard","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkl235","article-title":"Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus","volume":"58","author":"Leuthner","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.37.2.281","article-title":"Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients","volume":"37","author":"Lamer","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0035","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1378\/chest.124.5.1789","article-title":"Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0045","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M07-A8. Wayne, PA: CLSI; 2008."},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0050","unstructured":"Vibativ prescribing information. http:\/\/www.astellas.us\/docs\/us\/VIBATIV_PI_Final.pdf [accessed 22 October 2010]."},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0055","unstructured":"Zyvox prescribing information. http:\/\/media.pfizer.com\/files\/products\/uspi_zyvox.pdf [accessed 22 October 2010]."},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0060","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0065","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1128\/AAC.01009-08","article-title":"Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model","volume":"53","author":"Rose","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0075","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jac\/dkl393","article-title":"Bactericidal agents in the treatment of MRSA infections\u2014the potential role of daptomycin","volume":"58","author":"French","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.02.007_bib0080","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1086\/425009","article-title":"The importance of bactericidal drugs: future directions in infectious disease","volume":"39","author":"Finberg","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791100104X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791100104X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T09:21:43Z","timestamp":1543828903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791100104X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S092485791100104X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.02.007","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}